In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Vericel, with a price target of $58.00. The company’s shares closed today at $34.94.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Cronin is a 2-star analyst with an average return of 0.5% and a 45.74% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Vericel, and Orthofix.
Vericel has an analyst consensus of Strong Buy, with a price target consensus of $58.00, a 66.00% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $55.00 price target.
VCEL market cap is currently $2.01B and has a P/E ratio of 1,029.37.
Read More on VCEL:
- Vericel’s Strong Growth and Operational Efficiency Justify Buy Rating Despite Slight Performance Miss
- Vericel reports Q2 EPS (1c), consensus (4c)
- Vericel reaffirms FY25 MACI revenue growth in low 20% range
- VCEL Upcoming Earnings Report: What to Expect?
- Vericel Poised for Strong Growth: Buy Rating Affirmed on Robust MACI Expansion and Burn Care Improvements